Trial Profile
Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by Coronary CTA (CCTA) and Microcalcification by F18-NaF PET: A Phase 3 Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Coronary artery disease; Hyperlipidaemia
- Focus Therapeutic Use
- 29 Aug 2023 Status changed from active, no longer recruiting to completed.
- 20 Jul 2022 Planned End Date changed from 31 Dec 2022 to 30 Jun 2023.
- 20 Jul 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Mar 2023.